[(2R,3S,4R,5R)-5-(3-carbamoyl-1,2,4-triazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (2S)-2-aminopropanoate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 三唑核糖核苷和核糖核苷酸
• 英文名称: [(2R,3S,4R,5R)-5-(3-carbamoyl-1,2,4-triazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (2S)-2-aminopropanoate
• 化学式: C₁₁H₁₇N₅O₆
• 分子量: 315.28
• InChiKey: GVZLPXMWICXSCL-DUXGTMBRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  176
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• MARKERS ASSOCIATED WITH RIBAVIRIN-INDUCED ANEMIA
  申请人：Albrecht Janice K.

  公开号：US20120282224A1

  公开（公告）日：2012-11-08

  The present invention provides genetic markers and biomarkers that are associated with anemia induced by ribavirin therapy. The genetic markers are located in the ITPA gene and elsewhere on human chromosome 20 and the biomarkers are low ITPA activity phenotypes. These markers of ribavirin-induced anemia are useful, inter alia, to identify patients who are least likely to develop anemia upon treatment with ribavirin pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with ribavirin, and in methods for selecting the most appropriate therapy for such patients.